Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Thomas Equels Insider Profile
4 Followers
Thomas Equels, CEO & President, Director at AIM ImmunoTech, holds 1.16M shares in AIM ImmunoTech (Ticker: AIM).
Thomas Equels AIM ImmunoTech (AIM)CEO & President, Director
AIM ImmunoTech (AIM)
CEO & President, Director
Ranked #96,082 out of 98,384 Corporate Insiders
Profitable Transactions
2 out of 35 Profitable Transactions
Average Return
-49.00%
Average return per transaction
Time Frame
Compare to
Insider Roles
CEO & President, Director
Roles that Thomas Equels holds in companies
Most Profitable Insider Trade
The most profitable trade made by Thomas Equels
Thomas Equels's Trading History
List of latest transactions for each holding click on a transaction to see Thomas Equels's performance on stock
You May Also Like
Thomas Equels insider profile FAQ
What is the percentage of profitable transactions made by Thomas Equels?
The percentage of profitable transactions made by Thomas Equels is 6%.
What is the average return per transaction made by Thomas Equels?
The average return per transaction made by Thomas Equels is -49.00%.
What stocks does Thomas Equels hold?
Thomas Equels holds: AIM stocks.
What was Thomas Equels’s latest transaction?
Thomas Equels latest transaction was an Uninformative Buy of $98.11K.
What was Thomas Equels's most profitable transaction?
Thomas Equels’s most profitable transaction was an Informative Buy of AIM stock on January 4, 2023. The return on the trade was 17.40%.
What is Thomas Equels's role in AIM ImmunoTech?
Thomas Equels's role in AIM ImmunoTech is CEO & President, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.